Synthetic biotechnology company Amyris Inc. has filed for a Chapter 11 bankruptcy and plans to sell its consumer brands and focus on developing its sustainable ingredients business.
In Bankruptcy, Amyris To Sell Consumer Brands, Turn Focus To Smaller Ingredients Business
Synthetic biotech company Amyris files for Chapter 11 bankruptcy for its multiple US corporate entities and plans to sell its consumer brands.
More from Ingredients & Safety
• By
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
• By
Supplements already under close scrutiny in the EU have been linked to severe adverse effects on the musculoskeletal system and liver, even at low doses.
• By
Australian government finds an insufficient body of new evidence to support Rx-to-OTC switch of erectile dysfunction drug sildenafil since it was last considered in 2020.
• By
It is well established that antibiotics disrupt the human gut microbiome, but what is not so well established is the use of probiotics to restore it, find the authors of a recently published scientific literature review.
More from HBW Insight
• By
Tariffs on imports from China and look at eliminating self-affirmed GRAS pathway introduced under Trump while DoJ Consumer Protection Branch also continues supplement sector priorities enduring across administrations.
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.